WO2013164592A1 - Pyrrolobenzodiazepines - Google Patents
Pyrrolobenzodiazepines Download PDFInfo
- Publication number
- WO2013164592A1 WO2013164592A1 PCT/GB2013/051097 GB2013051097W WO2013164592A1 WO 2013164592 A1 WO2013164592 A1 WO 2013164592A1 GB 2013051097 W GB2013051097 W GB 2013051097W WO 2013164592 A1 WO2013164592 A1 WO 2013164592A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound according
- nme
- group
- methyl
- alkyl
- Prior art date
Links
- 0 C*1C(C(*OC)=O)=CC(c2ccc(*C(C(*)=*(*)C(*)=CC)=O)cc2)=C1 Chemical compound C*1C(C(*OC)=O)=CC(c2ccc(*C(C(*)=*(*)C(*)=CC)=O)cc2)=C1 0.000 description 6
- GIFDVQUOPKITFR-UHFFFAOYSA-N CC(C)(C)OC(Nc(cc1)ccc1-c1c[n](C)c(C(O)=O)c1)=O Chemical compound CC(C)(C)OC(Nc(cc1)ccc1-c1c[n](C)c(C(O)=O)c1)=O GIFDVQUOPKITFR-UHFFFAOYSA-N 0.000 description 1
- KUULVKMOCXLWQV-UHFFFAOYSA-N C[n]1c(C(Nc2c[n](C)c(C(Nc3c[n](C)c(C(OC)=O)c3)=O)c2)=O)cc(-c(cc2)ccc2N)c1 Chemical compound C[n]1c(C(Nc2c[n](C)c(C(Nc3c[n](C)c(C(OC)=O)c3)=O)c2)=O)cc(-c(cc2)ccc2N)c1 KUULVKMOCXLWQV-UHFFFAOYSA-N 0.000 description 1
- IMWTWOGNUVGCHL-UHFFFAOYSA-N C[n]1c(C(Nc2c[n](C)c(C(OC)=O)c2)=O)cc(-c(cc2)ccc2N)c1 Chemical compound C[n]1c(C(Nc2c[n](C)c(C(OC)=O)c2)=O)cc(-c(cc2)ccc2N)c1 IMWTWOGNUVGCHL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- the present invention relates to pyrrolobenzodiazepines (PBDs) and in particular to PBD monomers and methods of synthesising PBD monomers.
- PBDs pyrrolobenzodiazepines
- PBDs pyrrolobenzodiazepines
- Family members include abbeymycin (Hochlowski, et al., J. Antibiotics, 40, 145-148 (1987)), chicamycin (Konishi, et al., J. Antibiotics, 37, 200-206 (1984)), DC-81 (Japanese Patent 58-180 487; Thurston, et al., Chem. Brit., 26, 767-772 (1990); Bose, et al., Tetrahedron, 48, 751-758 (1992)), mazethramycin (Kuminoto, et al., J. Antibiotics, 33, 665-667 (1980)), neothramycins A and B (Takeuchi, et al., J.
- a first aspect of the present invention provides a compound of formula I:
- the dotted double bond indicates the presence of a single or double bond between C2 and C3;
- R 7 is selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR ⁇ nitro, Me 3 Sn and halo; where R and R' are independently selected from optionally substituted Ci -7 alkyl, C 3 . 2 o heterocyclyl and C 5 . 2 o aryl groups;
- R 0 and R either together form a double bond, or are selected from H and QR Q respectively, where Q is selected from O, S and NH and R Q is H or Ci -7 alkyl or H and SO x M, where x is 2 or 3, and M is a monovalent pharmaceutically acceptable cation;
- A is selected from A1 , A2, A3, A4 or A5:
- X 1 and Y are selected from: CH and NH; CH and NMe; N and NMe; CH and S; N and S; N and O; and CH and O, respectively;
- X 2 and Y 2 are selected from: CH and NH; CH and NMe; N and NMe; CH and S; N and S; N and O; and CH and O, respectively;
- Z is selected from O and S
- Z 2 is selected from CH and N;
- F is selected from a single bond and -(E-F ) m -;
- each F is independently a C 3 . 2 o heteroarylene group
- n 1 , 2 or 3;
- G is selected from hydrogen, Ci -4 alkyl, -(CH 2 ) n -C3. 2 o heterocycloalkyl, and -0-(CH 2 ) n -C3-2o heterocycloalkyl group, and each n is 0-4;
- A2 is not A2':
- A3 is not A3':
- X 2 and Y 2 of A3' are selected from: CH and NMe; COH and NMe; CH and S; N and NMe; N and S, respectively;
- B in A2' and A3' is either a single bond or: where X and Y of B1 are selected from: CH and NMe; COH and NMe; CH and S; N and NMe; N and S, respectively; and
- R is C1.4 alkyl.
- a second aspect of the present invention provides a method of synthesis of a compound of formula I.
- a third aspect of the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of the first aspect of the invention and a pharmaceutically acceptable carrier or diluent.
- a fourth aspect of the present invention provides a compound of the first aspect of the invention for use in a method of therapy.
- a fifth aspect of the present invention provides the use of a compound of the first aspect of the invention in the manufacture of a medicament for the treatment of a bacterial infection.
- This aspect also provides a compound of the first aspect for use in a method of treatment of a bacterial infection.
- a sixth aspect of the present invention provides a method of treatment of a patient suffering from a bacterial infection, comprising administering to said patient a
- the compound of the invention may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated.
- the pharmaceutical composition may comprise one or more (e.g. two , three or four) further active agents.
- substituted refers to a parent group which bears one or more substitutents.
- substitutents refers to a chemical moiety which is covalently attached to, or if appropriate, fused to, a parent group.
- substituents are well known, and methods for their formation and introduction into a variety of parent groups are also well known. Examples of substituents are described in more detail below.
- Ci-7 alkyl refers to a monovalent moiety obtained by removing a hydrogen atom from a carbon atom of a hydrocarbon compound having from 1 to 7 carbon atoms, which may be aliphatic or alicyclic, and which may be saturated or unsaturated (e.g. partially unsaturated, fully unsaturated).
- alkyl includes the sub-classes alkenyl, alkynyl, cycloalkyl, etc., discussed below.
- saturated alkyl groups include, but are not limited to, methyl (Ci), ethyl (C 2 ), propyl (C 3 ), butyl (C 4 ), pentyl (C 5 ), hexyl (C 6 ) and heptyl (C 7 ).
- saturated linear alkyl groups include, but are not limited to, methyl (Ci), ethyl (C 2 ), n-propyl (C 3 ), n-butyl (C 4 ), n-pentyl (amyl) (C 5 ), n-hexyl (C 6 ) and n-heptyl (C 7 ).
- saturated branched alkyl groups include iso-propyl (C 3 ), iso-butyl (C 4 ), sec-butyl (C 4 ), tert-butyl (C 4 ), iso-pentyl (C 5 ), and neo-pentyl (C 5 ).
- C2-7 Alkenyl The term "C2-7 alkenyl" as used herein, pertains to an alkyl group having one or more carbon-carbon double bonds.
- C2-7 alkynyl The term "C2-7 alkynyl" as used herein, pertains to an alkyl group having one or more carbon-carbon triple bonds.
- unsaturated alkynyl groups include, but are not limited to, ethynyl (ethinyl, - C ⁇ CH) and 2-propynyl (propargyl, -CH 2 -C ⁇ CH).
- C3.7 cycloalkyl refers to an alkyl group which is also a cyclyl group; that is, a monovalent moiety obtained by removing a hydrogen atom from an alicyclic ring atom of a cyclic hydrocarbon (carbocyclic) compound, which moiety has from 3 to 7 carbon atoms, including from 3 to 7 ring atoms.
- cycloalkyl groups include, but are not limited to, those derived from:
- C 3 -2o heterocyclyl refers to a monovalent moiety obtained by removing a hydrogen atoms from a ring atom of a heterocyclic compound, which moiety has from 3 to 20 ring atoms, of which from 1 to 10 are ring heteroatoms.
- each ring has from 3 to 7 ring atoms, of which from 1 to 4 are ring heteroatoms.
- the prefixes e.g. C 3 -20, C3-7, C5-6, etc.
- the term "C 5 . 6 heterocyclyl”, as used herein, pertains to a heterocyclyl group having 5 or 6 ring atoms.
- monocyclic heterocyclyl groups include, but are not limited to, those derived from:
- N 2 imidazolidine (C 5 ), pyrazolidine (diazolidine) (C 5 ), imidazoline (C 5 ), pyrazoline (dihydropyrazole) (C 5 ), piperazine (C 6 );
- N 1 O 1 tetrahydrooxazole (C 5 ), dihydrooxazole (C 5 ), tetrahydroisoxazole (C 5 ),
- dihydroisoxazole C 5
- morpholine C 6
- tetrahydrooxazine C 6
- dihydrooxazine C 6
- oxazine C 6
- N 1 S 1 thiazoline (C 5 ), thiazolidine (C 5 ), thiomorpholine (C 6 );
- O 1 S 1 oxathiole (C 5 ) and oxathiane (thioxane) (C 6 ); and,
- substituted monocyclic heterocyclyl groups include those derived from saccharides, in cyclic form, for example, furanoses (C 5 ), such as arabinofuranose, lyxofuranose, ribofuranose, and xylofuranse, and pyranoses (C 6 ), such as allopyranose, altropyranose, glucopyranose, mannopyranose, gulopyranose, idopyranose,
- C5-2 0 aryl The term "C 5 . 2 o aryl", as used herein, pertains to a monovalent moiety obtained by removing from an aromatic ring atom of an aromatic compound, which moiety has from 3 to 20 ring atoms. Preferably, each ring has from 5 to 7 ring atoms.
- the prefixes e.g. C 3 -2 0 , C5-7, C5-6, etc.
- the term “C 5 . 6 aryl” as used herein, pertains to an aryl group having 5 or 6 ring atoms.
- the ring atoms may be all carbon atoms, as in "carboaryl groups".
- carboaryl groups include, but are not limited to, those derived from benzene (i.e. phenyl) (C 6 ), naphthalene (Ci 0 ), azulene (Ci 0 ), anthracene (C14), phenanthrene (Ci 4 ), naphthacene (Ci 8 ), and pyrene (Ci 6 ).
- aryl groups which comprise fused rings include, but are not limited to, groups derived from indane (e.g. 2,3-dihydro-1 H- indene) (C 9 ), indene (C 9 ), isoindene (C 9 ), tetraline (1 ,2,3,4-tetrahydronaphthalene (C1 0 ), acenaphthene (C12), fluorene (C1 3 ), phenalene (C1 3 ), acephenanthrene (C15), and aceanthrene (Ci 6 ).
- the ring atoms may include one or more heteroatoms, as in "heteroaryl groups". Examples of monocyclic heteroaryl groups include, but are not limited to, those derived from:
- N1O1 oxazole (C 5 ), isoxazole (C 5 ), isoxazine (C 6 );
- N 2 imidazole (1 ,3-diazole) (C 5 ), pyrazole (1 ,2-diazole) (C 5 ), pyridazine (1 ,2-diazine) (C 6 ), pyrimidine (1 ,3-diazine) (C 6 ) (e.g., cytosine, thymine, uracil), pyrazine (1 ,4-diazine) (C 6 );
- N 4 tetrazole (C 5 ).
- heteroaryl which comprise fused rings include, but are not limited to: C 9 (with 2 fused rings) derived from benzofuran (Oi), isobenzofuran (Oi), indole (Ni), isoindole (Ni), indolizine (Ni), indoline (Ni), isoindoline (Ni), purine (N 4 ) (e.g.
- benzimidazole N 2
- indazole N 2
- benzoxazole N1O1
- benzisoxazole N1O1
- benzodioxole (0 2 )
- benzofurazan N 2 Oi
- benzotriazole N 3
- benzothiofuran Si
- benzothiazole N1S1
- benzothiadiazole N 2 S
- Cio (with 2 fused rings) derived from chromene (Oi), isochromene (Oi), chroman (Oi), isochroman (Oi), benzodioxan (0 2 ), quinoline (Ni), isoquinoline (Ni), quinolizine (Ni), benzoxazine (N1O1), benzodiazine (N 2 ), pyridopyridine (N 2 ), quinoxaline (N 2 ), quinazoline (N 2 ), cinnoline (N 2 ), phthalazine (N 2 ), naphthyridine (N 2 ), pteridine (N 4 );
- Ci 3 (with 3 fused rings) derived from carbazole (N ⁇ , dibenzofuran (Oi),
- Ci 4 (with 3 fused rings) derived from acridine (N ⁇ , xanthene (Oi), thioxanthene (Si), oxanthrene (0 2 ), phenoxathiin (O1S1), phenazine (N 2 ), phenoxazine (N ⁇ d),
- N1S1 phenothiazine
- S 2 thianthrene
- Ni phenanthridine
- Ni phenanthroline
- N 2 phenazine
- arylene refers to a divalent moiety obtained by removing a hydrogen atom from each of two ring atoms of a aromatic compound as described above with reference to aryl, carboaryl and heteroaryl.
- Ci-7 alkoxy groups include, but are not limited to, -OMe (methoxy), -OEt (ethoxy), -O(nPr) (n-propoxy), -O(iPr) (isopropoxy), -O(nBu) (n-butoxy), -O(sBu) (sec-butoxy), -O(iBu) (isobutoxy), and -O(tBu) (tert-butoxy).
- Acetal -CH(OR )(OR 2 ), wherein R and R 2 are independently acetal substituents, for example, a Ci -7 alkyl group, a C 3 . 2 o heterocyclyl group, or a C 5 . 2 o aryl group, preferably a Ci -7 alkyl group, or, in the case of a "cyclic" acetal group, R and R 2 , taken together with the two oxygen atoms to which they are attached, and the carbon atoms to which they are attached, form a heterocyclic ring having from 4 to 8 ring atoms.
- acetal groups include, but are not limited to, -CH(OMe) 2 , -CH(OEt) 2 , and -CH(OMe)(OEt).
- Hemiacetal -CH(OH)(OR 1 ), wherein R is a hemiacetal substituent, for example, a Ci -7 alkyl group, a C 3 . 20 heterocyclyl group, or a C 5 . 20 aryl group, preferably a Ci -7 alkyl group.
- R is a hemiacetal substituent, for example, a Ci -7 alkyl group, a C 3 . 20 heterocyclyl group, or a C 5 . 20 aryl group, preferably a Ci -7 alkyl group.
- hemiacetal groups include, but are not limited to, -CH(OH)(OMe) and - CH(OH)(OEt).
- Ketal -CR(OR )(OR 2 ), where R and R 2 are as defined for acetals, and R is a ketal substituent other than hydrogen, for example, a C ⁇ . ⁇ alkyl group, a C 3 . 20 heterocyclyl group, or a C 5 . 20 aryl group, preferably a Ci -7 alkyl group.
- ketal groups include, but are not limited to, -C(Me)(OMe) 2 , -C(Me)(OEt) 2 , -C(Me)(OMe)(OEt), -C(Et)(OMe) 2 , - C(Et)(OEt) 2 , and -C(Et)(OMe)(OEt).
- hemiacetal groups include, but are not limited to, -C(Me)(OH)(OMe), -C(Et)(OH)(OMe), -C(Me)(OH)(OEt), and -C(Et)(OH)(OEt).
- Imino (imine): NR, wherein R is an imino substituent, for example, hydrogen, C -7 alkyl group, a C 3 . 20 heterocyclyl group, or a C 5 . 20 aryl group, preferably hydrogen or a Ci -7 alkyl group.
- Formyl (carbaldehyde, carboxaldehyde): -C( 0)H.
- R is an acyl substituent, for example, a Ci -7 alkyl group (also referred to as Ci -7 alkylacyl or C ⁇ . ⁇ alkanoyl), a C 3 . 2 o heterocyclyl group (also referred to as C 3 . 2 o heterocyclylacyl), or a C 5 . 2 o aryl group (also referred to as C 5 . 2 o arylacyl), preferably a Ci -7 alkyl group.
- a Ci -7 alkyl group also referred to as Ci -7 alkylacyl or C ⁇ . ⁇ alkanoyl
- C 3 . 2 o heterocyclyl group also referred to as C 3 . 2 o heterocyclylacyl
- C 5 . 2 o aryl group also referred to as C 5 . 2 o arylacyl
- Ci -7 alkyl group also referred to as Ci -7 alkylacyl or C ⁇ . ⁇ alkanoyl
- Carboxy (carboxylic acid): -C( 0)OH.
- Ester (carboxylate, carboxylic acid ester, oxycarbonyl): -C( 0)OR, wherein R is an ester substituent, for example, a Ci -7 alkyl group, a C 3 . 20 heterocyclyl group, or a C 5 . 20 aryl group, preferably a Ci -7 alkyl group.
- R is an acyloxy substituent, for example, a C -7 alkyl group, a C 3 . 20 heterocyclyl group, or a C 5 . 20 aryl group, preferably a C -7 alkyl group.
- Oxycarboyloxy: -OC( 0)OR, wherein R is an ester substituent, for example, a C -7 alkyl group, a C 3 . 20 heterocyclyl group, or a C 5 . 20 aryl group, preferably a C ⁇ . ⁇ alkyl group.
- aryl group preferably H or a Ci -7 alkyl group, or, in the case of a "cyclic" amino group, R and R 2 , taken together with the nitrogen atom to which they are attached, form a heterocyclic ring having from 4 to 8 ring atoms.
- Amino groups may be primary (-NH 2 ), secondary (-NHR 1 ), or tertiary (-NHR R 2 ), and in cationic form, may be quaternary (- + NR R 2 R 3 ).
- amino groups include, but are not limited to, -NH 2 , -N HCH3, -NHC(CH 3 ) 2 , -N(CH 3 ) 2 , -N(CH 2 CH 3 ) 2 , and -NHPh.
- cyclic amino groups include, but are not limited to, aziridino, azetidino, pyrrolidino, piperidino, piperazino, morpholino, and thiomorpholino.
- Amido (carbamoyl, carbamyl, aminocarbonyl, carboxamide): -C( 0)NR R 2 , wherein R and R 2 are independently amino substituents, as defined for amino groups.
- Thioamido (thiocarbamyl): -C( S)NR R 2 , wherein R and R 2 are independently amino substituents, as defined for amino groups.
- R and R 2 may together form a cyclic structure, as in for example, succinimidyl, maleimidyl, and phthalimidyl:
- R 2 and R 3 are independently amino substituents, as defined for amino groups, and R is a ureido substituent, for example, hydrogen, a Ci -7 alkyl group, a C 3 . 2 o heterocyclyl group, or a C 5 . 20 aryl group, preferably hydrogen or a Ci -7 alkyl group.
- ureido groups include, but are not limited to, -NHCONH 2 , - NHCONHMe, -NHCONHEt, -NHCONMe 2 , -NHCONEt 2 , -NMeCONH 2 , -NMeCONHMe, -NMeCONHEt, -NMeCONMe 2 , and -NMeCONEt 2 .
- Imino: NR, wherein R is an imino substituent, for example, for example, hydrogen, a Ci -7 alkyl group, a C 3 . 20 heterocyclyl group, or a C 5 . 20 aryl group, preferably H or a
- Isocyano -NC. Cyanato: -OCN. Isocyanato: -NCO. Thiocyano (thiocyanato): -SCN.
- Ci -7 alkylthio groups include, but are not limited to, -SCH 3 and -SCH 2 CH 3 .
- Disulfide -SS-R, wherein R is a disulfide substituent, for example, a Ci -7 alkyl group, a C3-20 heterocyclyl group, or a C 5 . 2 o aryl group, preferably a C ⁇ . ⁇ alkyl group (also referred to herein as C ⁇ . ⁇ alkyl disulfide).
- Ci -7 alkyl disulfide groups include, but are not limited to, -SSCH 3 and -SSCH 2 CH 3 .
- Sulfine (sulfinyl, sulfoxide): -S( 0)R, wherein R is a sulfine substituent, for example, a Ci -7 alkyl group, a C 3 .
- Sulfone (sulfonyl): -S( 0) 2 R, wherein R is a sulfone substituent, for example, a Ci -7 alkyl group, a C 3 . 20 heterocyclyl group, or a C 5 . 20 aryl group, preferably a Ci -7 alkyl group, including, for example, a fluorinated or perfluorinated C -7 alkyl group.
- Sulfinate (sulfinic acid ester): -S( 0)OR; wherein R is a sulfinate substituent, for example, a Ci -7 alkyl group, a C 3 . 2 o heterocyclyl group, or a C 5 . 2 o aryl group, preferably a Ci -7 alkyl group.
- R is a sulfinate substituent, for example, a Ci -7 alkyl group, a C 3 . 2 o heterocyclyl group, or a C 5 . 2 o aryl group, preferably a Ci -7 alkyl group.
- sulfinate groups include, but are not limited to,
- Sulfonate (sulfonic acid ester): -S( 0) 2 OR, wherein R is a sulfonate substituent, for example, a Ci -7 alkyl group, a C 3 . 20 heterocyclyl group, or a C 5 . 20 aryl group, preferably a Ci -7 alkyl group.
- R is a sulfonate substituent, for example, a Ci -7 alkyl group, a C 3 . 20 heterocyclyl group, or a C 5 . 20 aryl group, preferably a Ci -7 alkyl group.
- sulfonate groups include, but are not limited to,
- Sulfate: -OS( 0) 2 OR; wherein R is a sulfate substituent, for example, a Ci -7 alkyl group, a C 3 . 20 heterocyclyl group, or a C 5 . 20 aryl group, preferably a Ci -7 alkyl group.
- R and R 2 are independently amino substituents, as defined for amino groups.
- R is an amino substituent, as defined for amino groups.
- R is an amino substituent, as defined for amino groups, and R is a sulfonamino substituent, for example, a d_ 7 alkyl group, a C 3 . 20 heterocyclyl group, or a C 5 . 20 aryl group, preferably a Ci_ 7 alkyl group.
- phosphino groups include, but are not limited to, -PH 2 , -P(CH 3 ) 2 , -P(CH 2 CH 3 ) 2 , -P(t-Bu) 2 , and -P(Ph) 2 .
- R is a phosphinyl substituent, for example, a C -7 alkyl group, a C 3 . 20 heterocyclyl group, or a C 5 . 20 aryl group, preferably a Ci -7 alkyl group or a C 5 . 20 aryl group.
- Phosphonic acid phosphono
- Phosphonate phosphono ester
- R is a phosphonate substituent, for example, -H, a Ci -7 alkyl group, a C 3 . 2 o heterocyclyl group, or a C 5 . 2 o aryl group, preferably -H, a Ci -7 alkyl group, or a C 5 . 2 o aryl group.
- Phosphorous acid -OP(OH) 2 .
- Phosphite -OP(OR) 2 , where R is a phosphite substituent, for example, -H, a Ci -7 alkyl group, a C 3 . 20 heterocyclyl group, or a C 5 . 20 aryl group, preferably -H, a C ⁇ . ⁇ alkyl group, or a C 5 . 20 aryl group.
- R is a phosphite substituent, for example, -H, a Ci -7 alkyl group, a C 3 . 20 heterocyclyl group, or a C 5 . 20 aryl group, preferably -H, a C ⁇ . ⁇ alkyl group, or a C 5 . 20 aryl group.
- phosphite groups include, but are not limited to,
- Phosphoramidite -OP(OR )-l ⁇ IR 2 2 , where R and R 2 are phosphoramidite substituents, for example, -H, a (optionally substituted) Ci -7 alkyl group, a C 3 . 20 heterocyclyl group, or a C 5 . 20 aryl group, preferably -H, a Ci -7 alkyl group, or a C 5 . 20 aryl group.
- Examples of phosphoramidite groups include, but are not limited to, -OP(OCH 2 CH 3 )-N(CH 3 ) 2 , -OP(OCH 2 CH 3 )-N(i-Pr) 2 , and -OP(OCH 2 CH 2 CN)-N(i-Pr) 2 .
- Examples of phosphoramidate groups include, but are not limited to,
- Nitrogen protecting groups are well known in the art. Preferred nitrogen protecting rbamate protecting groups that have the general formula:
- Particularly preferred protecting groups include Alloc, Troc, Teoc, BOC, Doc, Hoc, TcBOC, Fmoc, 1-Adoc and 2-Adoc.
- Hydroxyl protecting groups are well known in the art. A large number of suitable groups are described on pages 16 to 366 of Wuts, P.G.M. and Greene, T.W., Protective Groups in Organic Synthesis, 4 th Edition, Wley-lnterscience, 2007, which is incorporated herein by reference.
- Classes of particular interest include silyl ethers, methyl ethers, alkyl ethers, benzyl ethers, esters, benzoates, carbonates, and sulfonates.
- Particularly preferred protecting groups include THP.
- bacteria infection pertains to an invasion of body tissues by bacteria, their multiplication and the reaction of body tissues to the bacteria and the toxins that they produce.
- bacterial infectious disease pertains to a disease caused by bacteria.
- bacterial infections and infectious bacterial diseases include, but are not limited to, hospital- and community acquired infections due to Gram-positive bacteria such as Staphylococcus aureus, including multi-drug resistant forms such as methicillin- resistant S. aureus (MRSA), and to streptococci, including drug resistant forms such as vancomycin-resistant enterococci (VRE).
- Gram-positive bacteria such as Staphylococcus aureus
- MRSA methicillin-resistant S. aureus
- streptococci including drug resistant forms such as vancomycin-resistant enterococci (VRE).
- Other infections that could be treated include those due to Clostridium difficile, Listeria monocytogenes and skin infections due to Gram-positive bacteria.
- the compounds of the present invention are useful in the treatment of bacterial infections infectious bacterial diseases caused by bacterial infections involving drug resistant bacterial strains.
- Particularly preferred bacterial strains are
- the treatment is of a bacterial infectious disease or bacterial infection involving MRSA, vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and other infections due to drug resistant Gram-positive bacteria.
- MRSA vancomycin-intermediate S. aureus
- VRSA vancomycin-resistant S. aureus
- the present invention provides the use of a compound of the first aspect of the invention in a method of therapy.
- the term "therapeutically effective amount” is an amount sufficient to show benefit to a patient. Such benefit may be at least amelioration of at least one symptom.
- the actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage, is within the responsibility of general practitioners and other medical doctors.
- a compound may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated.
- treatments and therapies include, but are not limited to, ⁇ -lactam drugs such as the penicillins and cephalosporins, aminoglycosides, fluoroquinolones, oxazolidinones and the streptogramins.
- compositions according to the present invention may comprise, in addition to the active ingredient, i.e. a compound of formula I, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient.
- a pharmaceutically acceptable excipient e.g. cutaneous, subcutaneous, or intravenous.
- compositions for oral administration may be in tablet, capsule, powder or liquid form.
- a tablet may comprise a solid carrier or an adjuvant.
- Liquid pharmaceutical compositions generally comprise a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.
- a capsule may comprise a solid carrier such a gelatin.
- the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
- a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
- isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's
- Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.
- appropriate dosages of the compound can vary from patient to patient. Determining the optimal dosage will generally involve the balancing of the level of therapeutic benefit against any risk or deleterious side effects.
- the selected dosage level will depend on a variety of factors including, but not limited to, the activity of the particular compound, the route of administration, the time of administration, the rate of excretion of the compound, the duration of the treatment, other drugs, compounds, and/or materials used in combination, the severity of the condition, and the species, sex, age, weight, condition, general health, and prior medical history of the patient.
- the amount of compound and route of administration will ultimately be at the discretion of the physician, veterinarian, or clinician, although generally the dosage will be selected to achieve local concentrations at the site of action which achieve the desired effect without causing substantial harmful or deleterious side-effects.
- Administration can be effected in one dose, continuously or intermittently (e.g., in divided doses at appropriate intervals) throughout the course of treatment. Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and will vary with the formulation used for therapy, the purpose of the therapy, the target cell(s) being treated, and the subject being treated. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician, veterinarian, or clinician.
- a suitable dose of the active compound is in the range of about 100 ng to about 25 mg (more typically about 1 ⁇ g to about 10 mg) per kilogram body weight of the subject per day. Where the active compound is a salt, an ester, an amide, a prodrug, or the like, the amount administered is calculated on the basis of the parent compound and so the actual weight to be used is increased proportionately.
- the active compound is administered to a human patient according to the following dosage regime: about 100 mg, 3 times daily. In one embodiment, the active compound is administered to a human patient according to the following dosage regime: about 150 mg, 2 times daily.
- the active compound is administered to a human patient according to the following dosage regime: about 200 mg, 2 times daily.
- the appropriate dosage of the compound of the invention will depend on the type of disease to be treated, as defined above, the severity and course of the disease, whether the molecule is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody, and the discretion of the attending physician.
- the molecule is suitably administered to the patient at one time or over a series of treatments.
- about 1 ⁇ g/kg to 15 mg/kg (e.g. 0.1-20 mg/kg) of molecule is an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion.
- a typical daily dosage might range from about 1 ⁇ g/kg to 100 mg/kg or more, depending on the factors mentioned above.
- An exemplary dosage of compound to be administered to a patient is in the range of about 0.1 to about 10 mg/kg of patient weight.
- An exemplary dosing regimen comprises a course of administering an initial loading dose of about 4 mg/kg, followed by additional doses every week, two weeks, or three weeks of a compound. Other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.
- a reference to carboxylic acid (-COOH) also includes the anionic (carboxylate) form (-COO " ), a salt or solvate thereof, as well as conventional protected forms.
- a reference to an amino group includes the protonated form (-N + HR R 2 ), a salt or solvate of the amino group, for example, a hydrochloride salt, as well as conventional protected forms of an amino group.
- a reference to a hydroxyl group also includes the anionic form (-0 " ), a salt or solvate thereof, as well as conventional protected forms.
- Certain compounds may exist in one or more particular geometric, optical, enantiomeric, diasteriomeric, epimeric, atropic, stereoisomeric, tautomeric, conformational, or anomeric forms, including but not limited to, cis- and trans-forms; E- and Z-forms; c-, t-, and r- forms; endo- and exo-forms; R-, S-, and meso-forms; D- and L-forms; d- and I- forms; (+) and (-) forms; keto-, enol-, and enolate-forms; syn- and anti-forms; synclinal- and anticlinal-forms; a- and ⁇ -forms; axial and equatorial forms; boat-, chair-, twist-, envelope-, and halfchair-forms; and combinations thereof, hereinafter collectively referred to as "isomers” (or "isomeric forms").
- compounds of the present invention have the following stereochemistry at the C1 1 position:
- isomers are structural (or constitutional) isomers (i.e. isomers which differ in the connections between atoms rather than merely by the position of atoms in space).
- a reference to a methoxy group, -OCH 3 is not to be construed as a reference to its structural isomer, a hydroxymethyl group, -CH 2 OH.
- ortho-chlorophenyl is not to be construed as a reference to its structural isomer, meta-chlorophenyl.
- a reference to a class of structures may well include structurally isomeric forms falling within that class (e.g. Ci -7 alkyl includes n-propyl and iso-propyl; butyl includes n-, iso-, sec-, and tert-butyl; methoxyphenyl includes ortho-, meta-, and para-methoxyphenyl).
- keto/enol (illustrated below), imine/enamine, amide/imino alcohol, amidine/amidine, nitroso/oxime, thioketone/enethiol, N-nitroso/hyroxyazo, and nitro/aci-nitro.
- H may be in any isotopic form, including H, 2 H (D), and 3 H (T); C may be in any isotopic form, including 2 C, 3 C, and 4 C; O may be in any isotopic form, including 6 0 and 8 0; and the like.
- a reference to a particular compound includes all such isomeric forms, including (wholly or partially) racemic and other mixtures thereof.
- a reference to a particular compound also includes ionic, salt, solvate, and protected forms of thereof, for example, as discussed below.
- a corresponding salt of the active compound for example, a pharmaceutically-acceptable salt.
- a pharmaceutically-acceptable salt examples are discussed in Berge, et al., J. Pharm. Sci., 66, 1-19 (1977).
- a salt may be formed with a suitable cation.
- suitable inorganic cations include, but are not limited to, alkali metal ions such as Na + and K + , alkaline earth cations such as Ca 2+ and Mg 2+ , and other cations such as Al 3+ .
- suitable organic cations include, but are not limited to, ammonium ion (i.e. NH 4 + ) and substituted ammonium ions (e.g. NH 3 R + , NH 2 R2 + , NHR 3 + , NR 4 + ).
- suitable substituted ammonium ions are those derived from: ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine,
- phenylbenzylamine choline, meglumine, and tromethamine, as well as amino acids, such as lysine and arginine.
- amino acids such as lysine and arginine.
- An example of a common quaternary ammonium ion is N(CH 3 ) 4 + .
- a salt may be formed with a suitable anion.
- suitable inorganic anions include, but are not limited to, those derived from the following inorganic acids: hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfurous, nitric, nitrous, phosphoric, and phosphorous.
- Suitable organic anions include, but are not limited to, those derived from the following organic acids: 2-acetyoxybenzoic, acetic, ascorbic, aspartic, benzoic, camphorsulfonic, cinnamic, citric, edetic, ethanedisulfonic, ethanesulfonic, fumaric, glucheptonic, gluconic, glutamic, glycolic, hydroxymaleic, hydroxynaphthalene carboxylic, isethionic, lactic, lactobionic, lauric, maleic, malic, methanesulfonic, mucic, oleic, oxalic, palmitic, pamoic, pantothenic, phenylacetic, phenylsulfonic, propionic, pyruvic, salicylic, stearic, succinic, sulfanilic, tartaric, toluenesulfonic, and valeric.
- Suitable polymeric organic anions include, but are not limited to, those derived from the following polymeric acids: tannic acid, carboxymethyl cellulose.
- solvate is used herein in the conventional sense to refer to a complex of solute (e.g. active compound, salt of active compound) and solvent. If the solvent is water, the solvate may be conveniently referred to as a hydrate, for example, a mono-hydrate, a di-hydrate, a tri-hydrate, etc.
- Compounds of formula I include compounds where a nucleophilic solvent (H 2 0, R A OH, R A NH 2 , R A SH) adds across the imine bond of the PBD moiety, which is illustrated below where the solvent is water or an alcohol (R A OH, where R A is an ether substituent as described above):
- carbinolamine and carbinolamine ether forms of the PBD can be called the carbinolamine and carbinolamine ether forms of the PBD.
- the balance of these equilibria depend on the conditions in which the compounds are found, as well as the nature of the moiety itself.
- These compounds may be isolated in solid form, for example, by lyophilisation.
- R' 0 is a nitrogen protecting group and R' is O-R 2 , wherein R 2 is H or a hydroxyl protecting group.
- Such techniques are well known in the art, and are described, for example, in Wuts, P.G.M. and Greene, T.W., Protective Groups in Organic Synthesis, 4 th Edition, Wiley-lnterscience, 2007. If both nitrogen and hydroxyl protecting groups are present, these are preferably selected to be removable by the same conditions.
- R 0 and R will be H and QR Q respectively.
- these groups may be introduced by adding the compound to a different solvent to that in which the deprotection is carried out.
- R is a Ci_ 4 alkyl group, e.g. methyl.
- This deprotection of the carboxyl group may be carried out using standard means, e.g. treatment with base.
- butanoic acid side chain can be introduced at any stage in the synthesis, usually with appropriate protecting groups in place.
- the side chain can be formed by coupling a protected or precursor form to a hydroxy group on the bezene ring using e.g. Mitsunobo coupling.
- the ability of the compounds to bind to DNA, and in particular oligonucleotides, can be measured using an Ion Pair Reversed- Phase HPLC assay, as described in Rahman, K. M., et al., Journal of the American Chemical Society 2009, 131, 13756 and
- the DNA binding affinity can also be evaluated by using a calf-thymus DNA thermal denaturation assay, as described in Wells, G., et al., Journal of Medicinal Chemistry 2006, 49, 5442; Jenkins, T. C, et al., Journal of Medicinal Chemistry 1994, 37, 4529; and Gregson, S. J., et al., Journal of Medicinal Chemistry 2001 , 44, 737.
- the C2 carbon is a sp 2 centre, so that when R 2 is selected from any of the following groups:
- R 2 is selected from any of the following groups:
- R 2 is H.
- the configuration is configuration (C1).
- R 2 is R.
- R 2 is optionally substituted C 5 . 2 o aryl.
- R 2 When R 2 is optionally substituted C 5 . 2 o aryl, it may preferably be optionally substituted C 5 . 7 aryl or C 8 .io aryl- R 2 may further preferably be optionally substituted phenyl, optionally substituted napthyl, optionally substituted pyridyl, optionally substituted quinolinyl or isoquinolinyl. Of these groups, optionally susbtitued phenyl is most preferred.
- R 2 When R 2 is optionally substituted C 5 . 2 o aryl, it may preferably bear one to three substituent groups, with 1 and 2 being more preferred, and singly substituted groups being most preferred.
- the substituents may be any position.
- R 2 is a C 5 . 7 aryl group
- a single substituent is preferably on a ring atom that is not adjacent the bond to the remainder of the compound, i.e. it is preferably ⁇ or ⁇ to the bond to the remainder of the compound. Therefore, where the C 5 . 7 aryl group is phenyl, the substituent is preferably in the meta- or para- positions, and more preferably is in the para- position.
- R 2 is selected from:
- R 2 is a C 8 -io aryl group, for example quinolinyl or isoquinolinyl, it may bear any number of substituents at any position of the quinoline or isoquinoline rings. In some embodiments, it bears one, two or three substituents, and these may be on either the proximal and distal rings or both (if more than one substituent).
- R 2 When R 2 is optionally substituted C 5 . 2 o aryl, the substituents may be selected from: halo, hydroxyl, ether, formyl, acyl, carboxy, ester, acyloxy, amino, amido, acylamido, aminocarbonyloxy, ureido, nitro, cyano and thioether.
- the substituents When R 2 is optionally substituted C 5 . 2 o aryl, the substituents may be selected from the group consisting of R, OR, SR, NRR', N0 2 , halo, C0 2 R, COR, CONH 2 , CONHR, and CONRR'.
- a substituent on R 2 is halo, it is preferably F or CI, more preferably CI.
- a substituent on R 2 is ether, it may in some embodiments be an alkoxy group, for example, a Ci -7 alkoxy group (e.g. methoxy, ethoxy) or it may in some embodiments be a C 5 . 7 aryloxy group (e.g phenoxy, pyridyloxy, furanyloxy). If a substituent on R 2 is Ci -7 alkyl, it may preferably be a Ci_ 4 alkyl group (e.g. methyl, ethyl, propyl, butyl).
- a substituent on R 2 is C 3 . 7 heterocyclyl, it may in some embodiments be C 6 nitrogen containing heterocyclyl group, e.g. morpholino, thiomorpholino, piperidinyl, piperazinyl. These groups may be bound to the rest of the PBD moiety via the nitrogen atom. These groups may be further substituted, for example, by Ci_ 4 alkyl groups.
- R 2 is bis-oxy-Ci. 3 alkylene, this is preferably bis-oxy-methylene or bis- oxy-ethylene.
- substituents for R 2 include methoxy, ethoxy, fluoro, chloro, cyano, bis-oxy-methylene, methyl-piperazinyl, morpholino and methyl-thienyl.
- Particularly preferred substituted R 2 groups include, but are not limited to, 4-methoxy- phenyl, 3-methoxyphenyl, 4-ethoxy-phenyl, 3-ethoxy-phenyl, 4-fluoro-phenyl, 4-chloro- phenyl, 3,4-bisoxymethylene-phenyl, 4-methylthienyl, 4-cyanophenyl, 4-phenoxyphenyl, quinolin-3-yl and quinolin-6-yl, isoquinolin-3-yl and isoquinolin-6-yl, 2-thienyl, 2-furanyl, methoxynaphthyl, and naphthyl.
- R 2 is optionally substituted C M2 alkyl.
- Ci_i 2 alkyl When R 2 is optionally substituted Ci_i 2 alkyl, it may be selected from:
- R 2 is Ci_ 5 saturated aliphatic alkyl, it may be methyl, ethyl, propyl, butyl or pentyl. In some embodiments, it may be methyl, ethyl or propyl (n-pentyl or isopropyl). In some of these embodiments, it may be methyl. In other embodiments, it may be butyl or pentyl, which may be linear or branched.
- R 2 When R 2 is 0 3 . 6 saturated cycloalkyl, it may be cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. In some embodiments, it may be cyclopropyl.
- each of R 21 , R 22 and R 23 are independently selected from H,
- one of R 2 , R 22 and R 23 is H, with the other two groups being selected from H, Ci_ 3 saturated alkyl, C 2 -3 alkenyl, C 2 -3 alkynyl and cyclopropyl.
- two of R 2 , R 22 and R 23 are H, with the other group being selected from H, Ci-3 saturated alkyl, C 2 -3 alkenyl, C 2 -3 alkynyl and cyclopropyl.
- the groups that are not H are selected from methyl and ethyl. In some of these embodiments, the groups that are not H are methyl.
- R 2 is H. In some embodiments, R 22 is H.
- R 23 is H.
- R 2 and R 22 are H.
- R 2 and R 23 are H.
- R and R are H.
- R 25a and R 25 are H and the other is selected from: phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl.
- the group which is not H is optionally substituted phenyl.
- the phenyl optional substituent is halo, it is preferably fluoro.
- the phenyl group is unsubstituted.
- R 24 is selected from: H; Ci_ 3 saturated alkyl; C 2 . 3 alkenyl; C 2 . 3 alkynyl; cyclopropyl; phenyl, which phenyl is optionally substituted by a group selected from halo methyl, methoxy; pyridyl; and thiophenyl. If the phenyl optional substituent i halo, it is preferably fluoro. In some embodiment, the phenyl group is unsubstituted. In some embodiments, R 24 is selected from H, methyl, ethyl, ethenyl and ethynyl. In some of these embodiments, R 24 is selected from H and methyl.
- R 2 is halo or dihalo. In one embodiment, R 2 is -F or -F 2 , which substituents are illustrated below as (C3) and (C4) respectively:
- R 7 is selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR', nitro, Me 3 Sn and halo; R 7 may preferably be selected from H, OR, SH, SR, NH 2 , NHR, NRR', and halo.
- R 7 may more preferably be selected from H and OR.
- R 7 is OR, and more particularly OR 7A , where R 7A is independently optionally substituted d -7 alkyl.
- R 7A may be selected from optionally substituted saturated Ci -7 alkyl and optionally substituted C 2 . 4 alkenyl.
- R 7A may preferably be selected from Me, CH 2 Ph and allyl.
- R 0 and R either together form a double bond, or are selected from H and QR Q respectively, where Q is selected from O, S and NH and R Q is H or Ci -7 alkyl or H and SO x M, where x is 2 or 3, and M is a monovalent pharmaceutically acceptable cation;
- R 0 and R form a double bond together.
- R 0 is H and R is OR Q .
- R Q may preferably be selected from H or Me.
- R 0 is H and R is SO x M.
- x may preferably be 3, and M may preferably be Na + .
- R is Ci-4 alkyl.
- R may preferably be Ci_ 2 alkyl, and more preferably methyl.
- A is selected from A1 , A2, A3, A4 or A5.
- X 1 and X 2 are selected from A1 , A2, A3, A4 or A5.
- X 1 and Y are selected from: CH and NH; CH and NMe; N and NMe; CH and S; N and S; N and O; and CH and O, respectively.
- X 1 and Y are selected from: CH and NMe; N and NMe; CH and S; and CH and O, respectively. Most preferably, X 1 and Y are selected from N and NMe and CH and NMe, respectively.
- F is selected from a single bond and -(E-F ) m -.
- F is a C 5 . 6 heteroarylene group, more prefereably a C 5 heteroarylene group. More preferably, F is represented by structure F1 1 :
- X 3 and Y 3 are selected from: CH and NH; CH and NMe; N and NMe; CH and S; N and S; N and O; and CH and O, respectively.
- X 3 and Y 3 are selected from: CH and O; and CH and NMe, respectively.
- G is selected from hydrogen, Ci -4 alkyl, -(CH 2 )n-C3. 2 o heterocycloalkyl, and -0-(CH 2 ) n -C3-2o heterocycloalkyl group; and each n is 0-4.
- the C 3 . 2 o heterocycloalkyl group is a morphiline group.
- n is 0-4.
- n may be 0, 1 , 2, 3 or 4.
- G and at least one of the (-E-F 1 )- units of F are provided by the structures FG1 and FG2:
- FG1 and FG2 may be combined with other -(E-F 1 )- units of F if m is 2 or 3.
- a 1
- A1 is represented by the structure:
- Z is O or S.
- X 1 and Y are selected from CH and NMe, and N and NMe.
- A2 is represented by the structure: Preferably X 1 and Y are selected from CH and NMe, and N and NMe. Thus, preferred strucutres of A2 are A21 , A22, A23 and A24:
- -F-G is arranged in the para-position of the phenylene or pyridinyl group of A2.
- A2 When A2 is represented by structures A21 or A23, A may not be A2':
- X 1 and Y of A2' are selected from: CH and NMe and N and NMe, respectively; B is either a single bond or:
- X and Y of (B1) are selected from: CH and NMe; COH and NMe; CH and S; N and NMe; N and S, respectively; and
- R is Ci-4 alkyl.
- A3 is represented by the structure:
- X 1 and Y are selected from CH and NMe, N and NMe, and CH and O.
- X 2 and Y 2 are selected from CH and NMe, and N and NMe.
- A3 is A31 , A32, A33, A34, A35 and A36:
- the PBD portion of the compound is arranged in the para-position of the phenylene group of A3.
- A3 is represented by structures A31 or A32, A may not be A3':
- X 2 and Y 2 of A3' are selected from: CH and NMe; COH and NMe; CH and S; N and NMe; N and S, respectively;
- B is either a single bond or:
- X and Y of B1 are selected from: CH and NMe; COH and NMe; CH and S; N and NMe; N and S, respectively; and
- R is Ci-4 alkyl.
- A4 is represented by the structure:
- X 1 and Y are CH and O and Z is NMe.
- A4 is A41 :
- A5 is represented by the structure
- X 1 and Y are selected from CH and NMe, and CH and O. So preferred structures of A5 are given as A51 , A52, A53 and A54:
- Preferred compounds of the present invention are as follows:
- Compounds 26, 27, 28, 35, 54, and 56 are preferred. Compounds 26, 27, and 35 are more preferred, and compound 35 is particularly preferred.
- Optical rotations were measured on an ADP 220 polarimeter (Bellingham Stanley Ltd) and concentrations (c) are given in g/100ml_. Melting points were measured using a digital melting point apparatus (Electrothermal). IR spectra were recorded on a Perkin- Elmer Spectrum 1000 FT IR Spectrometer. H and 3 C NMR spectra were acquired at 300 K using a Bruker Advance NMR spectrometer at 400 and 100 MHz, respectively.
- Waters Micromass ZQ parameters used were: Capillary (kV), 3.38; Cone (V), 35; Extractor (V), 3.0; Source temperature (°C), 100; Desolvation Temperature (°C), 200; Cone flow rate (L/h), 50; De-solvation flow rate (L/h), 250.
- High- resolution mass spectrometry data were recorded on a Waters Micromass QTOF Global in positive W-mode using metal-coated borosilicate glass tips to introduce the samples into the instrument.
- Thin Layer Chromatography (TLC) was performed on silica gel aluminum plates (Merck 60, F 2 5 4 ), and flash chromatography utilized silica gel (Merck 60, 230-400 mesh ASTM).
- NBS N-Bromosuccinimide, 2.36 g, 13.24 mmol, 1.0 equiv.
- 2-(trichloroacetyl)-1-methylpyrrole (2) (3 g, 13.24 mmol, 1.0 equiv.) in anhydrous THF (35 mL) at -10°C.
- the reaction mixture was kept at -10°C for 2 hours and then left to reach room temperature (ca. 4 hours).
- Excess THF was evaporated in vacuum and the solid was re-dissolved in a mixture of EtOAc/n-hexane (1 :9).
- the resulting mixture was filtered through a plug of silica, and the filtrate was evaporated in vacuo.
- the reaction vessel was flushed with nitrogen during each addition.
- the reaction mixture was sealed in an inert N 2 atmosphere and heated with microwave radiation in an EMRYSTM Optimizer Microwave Station (Personal Chemistry) at 100°C for 12 minutes.
- EMRYSTM Optimizer Microwave Station Personal Chemistry
- the cooled reaction mixture was diluted with water (50 mL), extracted with EtOAc (3 x 40 mL), the filtrates combined, dried over MgS0 4 and concentrated under vacuum.
- the resulting oil was subjected to flash chromatography (n-hexane/EtOAc 9: 1) to give 5 (Yield - 2.2 g, 97%).
- Lithium hydroxide (68 mg, 1.65 mmol, 3 eq) was added to 9a (0.25 g, 0.55 mmol) in aqueous dioxane (8 ml dioxane, 4 ml water) at room temperature. The reaction mixture was stirred for 3 hours at which point TLC showed completion of reaction. Dioxane was evaporated under high vacuum and the residue was diluted with water. The resulting solution was acidified with 1 M citric acid followed by extraction with ethyl acetate (2 x 50 mL).
- boc protected 6 (0.94 mmol, 1.2 eq) was dissolved in DMF (5 mL) to which 2.0 eq of EDCI and 2.5 eq of DMAP were added. The mixture was allowed to stir for 30 minutes after which commercially available methyl 4-amino-1-methyl-1 H-imidazole-2- carboxylate (0.121 g, 0.79 mmol, 1.0 eq) was added. The reaction mixture was allowed to stir for a further 6 hour at which point TLC showed completion of reaction. The reaction was quenched by pouring it onto a mixture of ice/water mixture and the resulting mixture was extracted with ethyl acetate (3 x 150 mL).
- Dioxane was evaporated under high vacuum and the residue was diluted with water.
- the resulting solution was acidified with 1 M citric acid followed by extraction with ethyl acetate (2 x 100 ml_).
- the combied organic layers were washed with brine (100 ml_), dried over MgS0 4 and finally concentrated using a rotary evaporator under reduced pressure.
- the reaction was quenched by pouring it onto a mixture of ice/water mixture and the resulting mixture was extracted with ethyl acetate (3 x 150 ml_).
- the combined extracts were sequentially washed with citric acid (200 ml_), saturated aqueous NaHC0 3 (250 ml_), water (250 ml_), brine (250 ml_) and finally dried over MgS0 4 .
- Excess ethyl acetate was evaporated by rotary evaporator under reduced pressure and the crude product (1.88 gm) was used for hydrolysis reaction to afford 14a.
- Lithium hydroxide (0.24 g, 5.71 mmol, 3 eq) was added to the crude product (1.88 g, 2.87 mmol) in aqueous dioxane (75 ml dioxane, 11.5 ml water) at room temperature. The reaction mixture was stirred for 3 hours at which point TLC showed completion of reaction.
- Methicillin resistant Staphylococcus aureus (MRSA) strains EMRSA-15 and EMRSA-16 were isolated from clinical material at the Royal Free Hospital, London; MRSA strain
- BB568 was a gift from Brigitte Berger-Bachi, Institute of Medical Microbiology, University of Zurich, Switzerland.
- the community-associated MRSA isolate USA300 was purchased from the American Type Culture Collection as BAA-1556.
- S. aureus VISA strain Mu50 is a MRSA clinical isolate with vancomycin-intermediate resistance and was isolated and provided by Keiichi Hiramatsu, Juntendo University, Tokyo.
- ATCC 29213 is an antibiotic susceptible S. aureus reference strain. Vancomycin resistant enterococcal isolates E. faecalis ⁇ /RE ⁇ and E. faecium VRE10 were isolated at the Royal Free Hospital.
- MICs of antibacterial agents were determined by the CLSI broth microplate assay as previously described (Hadjivassileva T, Stapleton PD, Thurston DE et al. Interactions of pyrrolobenzodiazepine dimers and duplex DNA from methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 2007; 290: 672-678); agents were dissolved in DMSO prior to dilution in broth. At the concentrations used, the solvent had no effect on bacterial growth. Three MIC determinations per strain were performed in duplicate for each compound tested. PBD Minimum inhibitory concentration (MIC mg/L)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2014013144A MX2014013144A (en) | 2012-04-30 | 2013-04-30 | Pyrrolobenzodiazepines. |
EP13720502.7A EP2855481A1 (en) | 2012-04-30 | 2013-04-30 | Pyrrolobenzodiazepines |
IN2175MUN2014 IN2014MN02175A (en) | 2012-04-30 | 2013-04-30 | |
AU2013255612A AU2013255612B2 (en) | 2012-04-30 | 2013-04-30 | Pyrrolobenzodiazepines |
NZ701478A NZ701478A (en) | 2012-04-30 | 2013-04-30 | Pyrrolobenzodiazepines |
JP2015509487A JP6125614B2 (en) | 2012-04-30 | 2013-04-30 | Pyrrolobenzodiazepine |
CN201380035161.8A CN104540827B (en) | 2012-04-30 | 2013-04-30 | Pyrrolobenzodiazepines are tall and erect |
US14/397,843 US9321774B2 (en) | 2012-04-30 | 2013-04-30 | Pyrrolobenzodiazepines |
BR112014027190-9A BR112014027190B1 (en) | 2012-04-30 | 2013-04-30 | PIRROLOBENZODIAZEPIN COMPOUND, ITS PHARMACEUTICAL COMPOSITION AND ITS USE |
CA2872205A CA2872205C (en) | 2012-04-30 | 2013-04-30 | Pyrrolobenzodiazepines |
KR1020147032596A KR101960130B1 (en) | 2012-04-30 | 2013-04-30 | Pyrrolobenzodiazepines |
ZA2014/08043A ZA201408043B (en) | 2012-04-30 | 2014-11-04 | Pyrrolobenzodiazepines |
HK15108789.1A HK1208217A1 (en) | 2012-04-30 | 2015-09-09 | Pyrrolobenzodiazepines |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261640316P | 2012-04-30 | 2012-04-30 | |
US61/640,316 | 2012-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013164592A1 true WO2013164592A1 (en) | 2013-11-07 |
Family
ID=48289484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2013/051097 WO2013164592A1 (en) | 2012-04-30 | 2013-04-30 | Pyrrolobenzodiazepines |
Country Status (14)
Country | Link |
---|---|
US (1) | US9321774B2 (en) |
EP (1) | EP2855481A1 (en) |
JP (1) | JP6125614B2 (en) |
KR (1) | KR101960130B1 (en) |
CN (1) | CN104540827B (en) |
AU (1) | AU2013255612B2 (en) |
BR (1) | BR112014027190B1 (en) |
CA (1) | CA2872205C (en) |
HK (1) | HK1208217A1 (en) |
IN (1) | IN2014MN02175A (en) |
MX (1) | MX2014013144A (en) |
NZ (1) | NZ701478A (en) |
WO (1) | WO2013164592A1 (en) |
ZA (1) | ZA201408043B (en) |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9388187B2 (en) | 2011-10-14 | 2016-07-12 | Medimmune Limited | Pyrrolobenzodiazepines |
US9387259B2 (en) | 2011-10-14 | 2016-07-12 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
US9399641B2 (en) | 2011-09-20 | 2016-07-26 | Medimmune Limited | Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates |
US9399073B2 (en) | 2011-10-14 | 2016-07-26 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines |
US9415117B2 (en) | 2012-10-12 | 2016-08-16 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US9526798B2 (en) | 2011-10-14 | 2016-12-27 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
US9562049B2 (en) | 2012-12-21 | 2017-02-07 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US9567340B2 (en) | 2012-12-21 | 2017-02-14 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
US9592240B2 (en) | 2010-04-15 | 2017-03-14 | Seattle Genetics Inc. | Targeted pyrrolobenzodiazapine conjugates |
US9624227B2 (en) | 2008-10-17 | 2017-04-18 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases |
US9649390B2 (en) | 2013-03-13 | 2017-05-16 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
WO2017098257A1 (en) * | 2015-12-09 | 2017-06-15 | King's College London | Pbd antibacterial agents |
US9732084B2 (en) | 2010-04-15 | 2017-08-15 | Medimmune Limited | Pyrrolobenzodiazepines used to treat proliferative diseases |
US9745303B2 (en) | 2012-10-12 | 2017-08-29 | Medimmune Limited | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
US9821074B2 (en) | 2013-03-13 | 2017-11-21 | Genentech, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
WO2017223275A1 (en) * | 2016-06-24 | 2017-12-28 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
US9889207B2 (en) | 2012-10-12 | 2018-02-13 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US9956298B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10029018B2 (en) | 2013-10-11 | 2018-07-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10143695B2 (en) | 2016-05-18 | 2018-12-04 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
US10392393B2 (en) | 2016-01-26 | 2019-08-27 | Medimmune Limited | Pyrrolobenzodiazepines |
US10420777B2 (en) | 2014-09-12 | 2019-09-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10543279B2 (en) | 2016-04-29 | 2020-01-28 | Medimmune Limited | Pyrrolobenzodiazepine conjugates and their use for the treatment of cancer |
US10695439B2 (en) | 2016-02-10 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
WO2020152462A1 (en) * | 2019-01-23 | 2020-07-30 | King's College London | Pyrrolobenzodiazepine derivatives as inhibitors of nf-kappa b for the treatment of proliferative diseases |
US10780096B2 (en) | 2014-11-25 | 2020-09-22 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
US10799595B2 (en) | 2016-10-14 | 2020-10-13 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US11160872B2 (en) | 2017-02-08 | 2021-11-02 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
WO2022023735A1 (en) | 2020-07-28 | 2022-02-03 | Femtogenix Limited | Cytotoxic agents |
US11352324B2 (en) | 2018-03-01 | 2022-06-07 | Medimmune Limited | Methods |
US11370801B2 (en) | 2017-04-18 | 2022-06-28 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US11517626B2 (en) | 2016-02-10 | 2022-12-06 | Medimmune Limited | Pyrrolobenzodiazepine antibody conjugates |
US11524969B2 (en) | 2018-04-12 | 2022-12-13 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof as antitumour agents |
US11583590B2 (en) | 2017-09-29 | 2023-02-21 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor |
US11612665B2 (en) | 2017-02-08 | 2023-03-28 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US11638760B2 (en) | 2017-11-27 | 2023-05-02 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
US11649250B2 (en) | 2017-08-18 | 2023-05-16 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
WO2024127332A1 (en) | 2022-12-14 | 2024-06-20 | Pheon Therapeutics Ltd | Cytotoxic compounds |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX364329B (en) | 2012-10-12 | 2019-04-23 | Medimmune Ltd | Pyrrolobenzodiazepine-antibody conjugates. |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
CA3057748A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
UA127900C2 (en) | 2017-06-14 | 2024-02-07 | Ейдісі Терапьютікс Са | Dosage regimes for the administration of an anti-cd19 adc |
KR20210086557A (en) | 2019-12-31 | 2021-07-08 | 주식회사 레고켐 바이오사이언스 | Pyrrolobenzodiazepine derivatives and its ligand-linker conjugate |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2053894A (en) | 1979-07-17 | 1981-02-11 | Green Cross Corp | Benzodiazepines processes for producing them and compositions containing them |
JPS58180487A (en) | 1982-04-16 | 1983-10-21 | Kyowa Hakko Kogyo Co Ltd | Antibiotic dc-81 and its preparation |
WO2000012506A2 (en) | 1998-08-27 | 2000-03-09 | Spirogen Limited | Collections of compounds |
WO2005085177A2 (en) | 2004-03-01 | 2005-09-15 | Spirogen Limited | Biaryl amino acids and their use in dna binding oligomers |
WO2007039752A1 (en) | 2005-10-05 | 2007-04-12 | Spirogen Limited | Alkyl 4- [4- (5-oxo-2, 3, 5, 11a-tetrahyd0-5h-pyrr0l0 [2, 1-c] [1, 4] benzodiazepine-8-yloxy) -butyrylamino]-1h-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease |
WO2009060208A1 (en) * | 2007-11-09 | 2009-05-14 | Spirogen Limited | Pyrrolobenzodiazepines |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5569587A (en) | 1978-11-17 | 1980-05-26 | Meiji Seika Kaisha Ltd | Novel antibiotic neothramycin derivative and its preparation |
US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
US6187797B1 (en) | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
ATE236890T1 (en) | 1996-12-23 | 2003-04-15 | Bristol Myers Squibb Pharma Co | OXYGEN OR SULFUR CONTAINING 5-MEMBED HETEROAROMATIC DERIVATIVES AS FACTOR XA INHIBITORS |
WO1999046244A1 (en) | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
AU757510C (en) | 1998-08-27 | 2003-09-11 | Medimmune Limited | Pyrrolobenzodiazepines |
GB9818732D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collection of compounds |
GB9818731D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
US6909006B1 (en) | 1999-08-27 | 2005-06-21 | Spirogen Limited | Cyclopropylindole derivatives |
US6613787B2 (en) | 1999-12-20 | 2003-09-02 | The University Of North Carolina At Chapel Hill | Compounds that exhibit specific molecular recognition of mixed nucleic acid sequences and bind in the DNA minor groove as a dimer |
US20020198254A1 (en) * | 2000-12-27 | 2002-12-26 | Velligan Mark D. | Polyamide analogs |
WO2002100832A1 (en) * | 2001-06-13 | 2002-12-19 | Genesoft Pharmaceuticals, Inc. | Isoquinoline compounds having antiinfective activity |
CA2459308A1 (en) * | 2001-09-07 | 2003-03-20 | Dale L. Boger | Cbi analogues of cc-1065 and the duocarmycins |
US20040138269A1 (en) | 2002-10-11 | 2004-07-15 | Sugen, Inc. | Substituted pyrroles as kinase inhibitors |
GB0226593D0 (en) | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
GB0321295D0 (en) | 2003-09-11 | 2003-10-15 | Spirogen Ltd | Synthesis of protected pyrrolobenzodiazepines |
WO2005032594A2 (en) * | 2003-10-03 | 2005-04-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Alkylators linked to polyamides as dna binding agents |
GB0404577D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
GB0404578D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
PL2270010T3 (en) | 2004-03-01 | 2012-07-31 | Medimmune Ltd | 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepins |
US7528126B2 (en) | 2004-03-09 | 2009-05-05 | Spirogen Limited | Pyrrolobenzodiazepines |
GB0410725D0 (en) | 2004-05-13 | 2004-06-16 | Spirogen Ltd | Pyrrolobenzodiazepine therapeutic agents |
NZ563136A (en) | 2005-04-21 | 2009-11-27 | Spirogen Ltd | Pyrrolobenzodiazepines |
US8406170B2 (en) | 2006-11-16 | 2013-03-26 | Telefonaktiebolaget Lm Ericsson (Publ) | Gateway selection mechanism |
GB0813432D0 (en) | 2008-07-22 | 2008-08-27 | Spirogen Ltd | Pyrrolobenzodiazepines |
GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
-
2013
- 2013-04-30 KR KR1020147032596A patent/KR101960130B1/en active IP Right Grant
- 2013-04-30 US US14/397,843 patent/US9321774B2/en not_active Expired - Fee Related
- 2013-04-30 IN IN2175MUN2014 patent/IN2014MN02175A/en unknown
- 2013-04-30 EP EP13720502.7A patent/EP2855481A1/en not_active Withdrawn
- 2013-04-30 CA CA2872205A patent/CA2872205C/en not_active Expired - Fee Related
- 2013-04-30 AU AU2013255612A patent/AU2013255612B2/en not_active Ceased
- 2013-04-30 NZ NZ701478A patent/NZ701478A/en not_active IP Right Cessation
- 2013-04-30 JP JP2015509487A patent/JP6125614B2/en active Active
- 2013-04-30 CN CN201380035161.8A patent/CN104540827B/en not_active Expired - Fee Related
- 2013-04-30 WO PCT/GB2013/051097 patent/WO2013164592A1/en active Application Filing
- 2013-04-30 MX MX2014013144A patent/MX2014013144A/en unknown
- 2013-04-30 BR BR112014027190-9A patent/BR112014027190B1/en not_active IP Right Cessation
-
2014
- 2014-11-04 ZA ZA2014/08043A patent/ZA201408043B/en unknown
-
2015
- 2015-09-09 HK HK15108789.1A patent/HK1208217A1/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2053894A (en) | 1979-07-17 | 1981-02-11 | Green Cross Corp | Benzodiazepines processes for producing them and compositions containing them |
JPS58180487A (en) | 1982-04-16 | 1983-10-21 | Kyowa Hakko Kogyo Co Ltd | Antibiotic dc-81 and its preparation |
WO2000012506A2 (en) | 1998-08-27 | 2000-03-09 | Spirogen Limited | Collections of compounds |
WO2005085177A2 (en) | 2004-03-01 | 2005-09-15 | Spirogen Limited | Biaryl amino acids and their use in dna binding oligomers |
WO2007039752A1 (en) | 2005-10-05 | 2007-04-12 | Spirogen Limited | Alkyl 4- [4- (5-oxo-2, 3, 5, 11a-tetrahyd0-5h-pyrr0l0 [2, 1-c] [1, 4] benzodiazepine-8-yloxy) -butyrylamino]-1h-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease |
WO2009060208A1 (en) * | 2007-11-09 | 2009-05-14 | Spirogen Limited | Pyrrolobenzodiazepines |
Non-Patent Citations (37)
Title |
---|
ARIMA ET AL., J. ANTIBIOTICS, vol. 25, 1972, pages 437 - 444 |
BARALDI, P.G., JOURNAL OF MEDICINAL CHEMISTRY, vol. 42, no. 25, 1999, pages 5131 - 5141 |
BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19 |
BOSE ET AL., TETRAHEDRON, vol. 48, 1992, pages 751 - 758 |
DAMAYANTHI, Y. ET AL., JOURNAL OF ORGANIC CHEMISTRY, vol. 64, no. 1, 1999, pages 290 - 292 |
FEDERICO BRUCOLI ET AL: "Novel C8-linked pyrrolobenzodiazepine (PBD)heterocycle conjugates that recognize DNA sequences containing an inverted CCAAT box", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 21, no. 12, 12 April 2011 (2011-04-12), pages 3780 - 3783, XP028387847, ISSN: 0960-894X, [retrieved on 20110420], DOI: 10.1016/J.BMCL.2011.04.054 * |
GREGSON, S. J. ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 44, 2001, pages 737 |
HADJIVASSILEVA T; STAPLETON PD; THURSTON DE ET AL.: "Interactions of pyrrolobenzodiazepine dimers and duplex DNA from methicillin-resistant Staphylococcus aureus", INT J ANTIMICROB AGENTS, vol. 290, 2007, pages 672 - 678 |
HARA ET AL., J. ANTIBIOTICS, vol. 41, 1988, pages 702 - 704 |
HOCHLOWSKI ET AL., J. ANTIBIOTICS, vol. 40, 1987, pages 145 - 148 |
HURLEY; NEEDHAM-VANDEVANTER, ACC. CHEM. RES., vol. 19, 1986, pages 230 - 237 |
ITOH ET AL., J. ANTIBIOTICS, vol. 41, 1988, pages 1281 - 1284 |
JENKINS, T. C. ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 37, 1994, pages 4529 |
KHONDAKER M. RAHMAN ET AL: "Biaryl polyamides as a new class of DNA quadruplex-binding ligands", CHEMICAL COMMUNICATIONS, no. 27, 5 July 2009 (2009-07-05), pages 4097 - 4099, XP055069947, ISSN: 1359-7345, DOI: 10.1039/b902359c * |
KHONDAKER M. RAHMAN ET AL: "GC-Targeted C8-Linked Pyrrolobenzodiazepine-Biaryl Conjugates with Femtomolar in Vitro Cytotoxicity and in Vivo Antitumor Activity in Mouse Models", JOURNAL OF MEDICINAL CHEMISTRY, vol. 56, no. 7, 11 April 2013 (2013-04-11), pages 2911 - 2935, XP055069332, ISSN: 0022-2623, DOI: 10.1021/jm301882a * |
KOHN: "Antibiotics III", 1975, SPRINGER-VERLAG, pages: 3 - 11 |
KONISHI ET AL., J. ANTIBIOTICS, vol. 37, 1984, pages 200 - 206 |
KUMAR, R. ET AL., HETEROCYCLIC COMMUNICATIONS, vol. 8, no. 1, 2002, pages 19 - 26 |
KUMAR, R; LOWN, J.W., ONCOLOGY RESEARCH, vol. 13, no. 4, 2003, pages 221 - 233 |
KUMINOTO ET AL., J. ANTIBIOTICS, vol. 33, 1980, pages 665 - 667 |
LANGLEY; THURSTON, J. ORG. CHEM., vol. 52, 1987, pages 91 - 97 |
LEBER ET AL., J. AM. CHEM. SOC., vol. 110, 1988, pages 2992 - 2993 |
LEIMGRUBER ET AL., J. AM. CHEM. SOC., vol. 87, 1965, pages 5791 - 5793 |
LEIMGRUBER ET AL., J. AM. CHEM. SOC., vol. 87, 1965, pages 5793 - 5795 |
NARAYANASWAMY, M. ET AL., ANALYTICAL BIOCHEMISTRY, vol. 374, 2008, pages 173 |
RAHMAN, K. M. ET AL., JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 131, 2009, pages 13756 |
See also references of EP2855481A1 * |
SHIMIZU ET AL., J. ANTIBIOTICS, vol. 35, 1982, pages 972 - 978 |
TAKEUCHI ET AL., J. ANTIBIOTICS, vol. 29, 1976, pages 93 - 96 |
THURSTON ET AL., CHEM. BRIT., vol. 26, 1990, pages 767 - 772 |
THURSTON ET AL., CHEM. REV., 1994, pages 433 - 465 |
THURSTON, D.E. ET AL., CHEM. REV., vol. 111, 2011, pages 2815 - 2864 |
THURSTON, D.E. ET AL., CHEM. REV., vol. 94, 1994, pages 433 - 465 |
TSUNAKAWA ET AL., J. ANTIBIOTICS, vol. 41, 1988, pages 1366 - 1373 |
WELLS, G. ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 49, 2006, pages 5442 |
WELLS, G. ET AL., PROC. AM. ASSOC. CANC. RES., vol. 44, 2003, pages 452 |
WUTS, P.G.M.; GREENE, T.W.: "Protective Groups in Organic Synthesis, 4th Edition,", 2007, WILEY-INTERSCIENCE |
Cited By (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9624227B2 (en) | 2008-10-17 | 2017-04-18 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases |
US9592240B2 (en) | 2010-04-15 | 2017-03-14 | Seattle Genetics Inc. | Targeted pyrrolobenzodiazapine conjugates |
US9732084B2 (en) | 2010-04-15 | 2017-08-15 | Medimmune Limited | Pyrrolobenzodiazepines used to treat proliferative diseases |
US10561739B2 (en) | 2010-04-15 | 2020-02-18 | Seattle Genetics Inc. | Targeted pyrrolobenzodiazapine conjugates |
US9399641B2 (en) | 2011-09-20 | 2016-07-26 | Medimmune Limited | Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates |
US9399073B2 (en) | 2011-10-14 | 2016-07-26 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines |
US10329352B2 (en) | 2011-10-14 | 2019-06-25 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
US10328084B2 (en) | 2011-10-14 | 2019-06-25 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
US9526798B2 (en) | 2011-10-14 | 2016-12-27 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
US9713647B2 (en) | 2011-10-14 | 2017-07-25 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
US9388187B2 (en) | 2011-10-14 | 2016-07-12 | Medimmune Limited | Pyrrolobenzodiazepines |
US9387259B2 (en) | 2011-10-14 | 2016-07-12 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
US9707301B2 (en) | 2011-10-14 | 2017-07-18 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
US9889207B2 (en) | 2012-10-12 | 2018-02-13 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10646584B2 (en) | 2012-10-12 | 2020-05-12 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US9745303B2 (en) | 2012-10-12 | 2017-08-29 | Medimmune Limited | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
US9415117B2 (en) | 2012-10-12 | 2016-08-16 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10994023B2 (en) | 2012-10-12 | 2021-05-04 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10335497B2 (en) | 2012-10-12 | 2019-07-02 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US11701430B2 (en) | 2012-10-12 | 2023-07-18 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US9567340B2 (en) | 2012-12-21 | 2017-02-14 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
US9562049B2 (en) | 2012-12-21 | 2017-02-07 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10576164B2 (en) | 2013-03-13 | 2020-03-03 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US9649390B2 (en) | 2013-03-13 | 2017-05-16 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US9821074B2 (en) | 2013-03-13 | 2017-11-21 | Genentech, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
US10029018B2 (en) | 2013-10-11 | 2018-07-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US9956298B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10420777B2 (en) | 2014-09-12 | 2019-09-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10780096B2 (en) | 2014-11-25 | 2020-09-22 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
US10640507B2 (en) | 2015-12-09 | 2020-05-05 | King's College London | PBD antibacterial agents |
WO2017098257A1 (en) * | 2015-12-09 | 2017-06-15 | King's College London | Pbd antibacterial agents |
US10392393B2 (en) | 2016-01-26 | 2019-08-27 | Medimmune Limited | Pyrrolobenzodiazepines |
US10695439B2 (en) | 2016-02-10 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US11517626B2 (en) | 2016-02-10 | 2022-12-06 | Medimmune Limited | Pyrrolobenzodiazepine antibody conjugates |
US10543279B2 (en) | 2016-04-29 | 2020-01-28 | Medimmune Limited | Pyrrolobenzodiazepine conjugates and their use for the treatment of cancer |
US10660901B2 (en) | 2016-05-18 | 2020-05-26 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
US10143695B2 (en) | 2016-05-18 | 2018-12-04 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
CN109641910A (en) * | 2016-06-24 | 2019-04-16 | 梅尔莎纳医疗公司 | Pyrroles acene phenodiazine * and its conjugate |
WO2017223275A1 (en) * | 2016-06-24 | 2017-12-28 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
US10526294B2 (en) | 2016-06-24 | 2020-01-07 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
US10799595B2 (en) | 2016-10-14 | 2020-10-13 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US11160872B2 (en) | 2017-02-08 | 2021-11-02 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
US11612665B2 (en) | 2017-02-08 | 2023-03-28 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US11813335B2 (en) | 2017-02-08 | 2023-11-14 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US11370801B2 (en) | 2017-04-18 | 2022-06-28 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US11649250B2 (en) | 2017-08-18 | 2023-05-16 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US11583590B2 (en) | 2017-09-29 | 2023-02-21 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor |
US11628223B2 (en) | 2017-09-29 | 2023-04-18 | Daiichi Sankyo Company, Limited | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-α][1,4]diazepines |
US11638760B2 (en) | 2017-11-27 | 2023-05-02 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
US11352324B2 (en) | 2018-03-01 | 2022-06-07 | Medimmune Limited | Methods |
US11524969B2 (en) | 2018-04-12 | 2022-12-13 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof as antitumour agents |
WO2020152462A1 (en) * | 2019-01-23 | 2020-07-30 | King's College London | Pyrrolobenzodiazepine derivatives as inhibitors of nf-kappa b for the treatment of proliferative diseases |
WO2022023735A1 (en) | 2020-07-28 | 2022-02-03 | Femtogenix Limited | Cytotoxic agents |
WO2024127332A1 (en) | 2022-12-14 | 2024-06-20 | Pheon Therapeutics Ltd | Cytotoxic compounds |
Also Published As
Publication number | Publication date |
---|---|
JP2015516987A (en) | 2015-06-18 |
ZA201408043B (en) | 2017-08-30 |
NZ701478A (en) | 2016-08-26 |
BR112014027190B1 (en) | 2020-03-03 |
EP2855481A1 (en) | 2015-04-08 |
KR20150014935A (en) | 2015-02-09 |
US20150126495A1 (en) | 2015-05-07 |
IN2014MN02175A (en) | 2015-08-28 |
CN104540827A (en) | 2015-04-22 |
US9321774B2 (en) | 2016-04-26 |
AU2013255612A1 (en) | 2014-11-20 |
CA2872205A1 (en) | 2013-11-07 |
CN104540827B (en) | 2018-03-23 |
KR101960130B1 (en) | 2019-03-19 |
BR112014027190A2 (en) | 2017-06-27 |
JP6125614B2 (en) | 2017-05-10 |
AU2013255612B2 (en) | 2017-06-22 |
CA2872205C (en) | 2020-07-21 |
MX2014013144A (en) | 2015-05-11 |
HK1208217A1 (en) | 2016-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2013255612B2 (en) | Pyrrolobenzodiazepines | |
EP1723152B1 (en) | Pyrrolobenzodiazepines | |
US8940733B2 (en) | Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases | |
US7557099B2 (en) | Pyrrolobenzodiazepines as key intermediates in the synthesis of dimeric cytotoxic pyrrolobenzodiazepines | |
AU2003282251B2 (en) | Pyrrolobenzodiazepines | |
AU2011239522B2 (en) | Targeted pyrrolobenzodiazapine conjugates | |
WO2009060208A1 (en) | Pyrrolobenzodiazepines | |
US20080214525A1 (en) | Alkyl 4- [4- (5-Oxo-2,3,5, 11A-Tetrahydo-5H-Pyrrolo [2, 1-C] [1,4] Benzodiazepine-8-Yloxy) -Butyrylamino]-1H-Pyrrole-2-Carboxylate Derivatives and Related Compounds For the Treatment of a Proliferative Disease | |
WO2006111759A1 (en) | Pyrrolobenzodiazepines | |
JP2015534574A (en) | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13720502 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2872205 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14397843 Country of ref document: US Ref document number: MX/A/2014/013144 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2015509487 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20147032596 Country of ref document: KR Kind code of ref document: A Ref document number: 2013255612 Country of ref document: AU Date of ref document: 20130430 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014027190 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014027190 Country of ref document: BR Kind code of ref document: A2 Effective date: 20141030 |